Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mentor breast implant trial amended

This article was originally published in The Gray Sheet

Executive Summary

FDA approves a protocol change May 2 to the firm's 10-year post-approval study for its Memory Gel silicone-filled breast implants to allow patients to receive the implants even if they do not participate in the study. Access to Memory Gel will continue to be available only through physicians participating in the study (1"The Gray Sheet" Nov. 27, 2006, p. 3). Mentor says it has enrolled close to 4,000 patients in the 40,000-patient study since the implants' conditional approval in November...

You may also be interested in...



Sales Of Silicone Breast Implants To Easily Offset Post-Approval Study Costs

Mentor expects to spend up to $45 mil. over the next 10 years on an extensive post-approval study of its Memory Gel silicone-gel breast implants

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel